Showing results (2251-2260 of 3,353) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|November 19, 2008
Modelling downstream effects in the presence of technological changeDuncan MortimerPharmacoeconomics|July 21, 2007
When drugs don't work: economic assessment of enhancing compliance with interventions supported by electronic monitoring devicesDyfrig HughesPharmacoeconomics|January 31, 2009
Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin's lymphomaPhilippe Fagnoni, Noel Milpied, Samuel Limat, et al.Pharmacoeconomics|April 10, 2009
Cost of illness of glaucoma: a critical and systematic reviewRichard G Fiscella, Jeff Lee, Elizabeth J H Davis, et al.Pharmacoeconomics|April 10, 2009
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1Peter Lindgren, Martin Buxton, Thomas Kahan, et al.Pharmacoeconomics|November 6, 2022
Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A TutorialNathan Green, Felicity Lamrock, Nichola Naylor, et al.Pharmacoeconomics|October 10, 2022
A Value Set for the EQ-5D-Y-3L in the NetherlandsBram Roudijk, Ayesha Sajjad, Brigitte Essers, et al.Pharmacoeconomics|September 29, 2022
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid LeukemiaRumjhum Agrawal, Joao Vieira, Jacqueline Ryan, et al.Pharmacoeconomics|September 7, 2022
Engaging Patients and Caregivers in an Early Health Economic Evaluation: Discerning Treatment Value Based on Lived ExperienceMackenzie Wilson, Kednapa Thavorn, Terry Hawrysh, et al.Pharmacoeconomics|August 29, 2022
The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USAAli Tafazzoli, Scott D Ramsey, Alissa Shaul, et al.Pageof 336